Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Amanda Clarke

Showing results (71-80 of 124) with videos related to

Pageof 13
Sort By:
Public Health Research (Southampton, England)|October 27, 2025
Home-based intervention strategy to reduce new chlamydia infection among young men: the HIS-UK RCTNicole Stone, Cynthia Graham, Rowena Bedford, et al.
The Lancet. Public Health|September 5, 2020
Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective studyNadia Hanum, Valentina Cambiano, Janey Sewell, et al.
International Journal of STD & AIDS|April 14, 2025
Post-acute sequelae of COVID-19 in people of Black ethnicities living with HIV in the United KingdomZoe Ottaway, Lucy Campbell, Julie Fox, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
AIDS (London, England)|September 16, 2015
Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analoguesAndrea Antinori, Amanda Clarke, Veronika Svedhem-Johansson, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trialDarrell H S Tan, Janet M Raboud, Leah Szadkowski, et al.
Antiviral Therapy|March 24, 2020
Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Saye Khoo, et al.
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Plos Medicine|June 18, 2021
Trends in HIV incidence between 2013-2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort studyNadia Hanum, Valentina Cambiano, Janey Sewell, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
Pageof 13

Showing results (71-80 of 124) with videos related to

Sort By:
Pageof 13
Public Health Research (Southampton, England)|October 27, 2025
Home-based intervention strategy to reduce new chlamydia infection among young men: the HIS-UK RCTNicole Stone, Cynthia Graham, Rowena Bedford, et al.
The Lancet. Public Health|September 5, 2020
Use of HIV pre-exposure prophylaxis among men who have sex with men in England: data from the AURAH2 prospective studyNadia Hanum, Valentina Cambiano, Janey Sewell, et al.
International Journal of STD & AIDS|April 14, 2025
Post-acute sequelae of COVID-19 in people of Black ethnicities living with HIV in the United KingdomZoe Ottaway, Lucy Campbell, Julie Fox, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 16, 2014
Cerebrospinal fluid exposure of efavirenz and its major metabolites when dosed at 400 mg and 600 mg once daily: a randomized controlled trialAlan Winston, Janaki Amin, Amanda Clarke, et al.
AIDS (London, England)|September 16, 2015
Week 48 efficacy and central nervous system analysis of darunavir/ritonavir monotherapy versus darunavir/ritonavir with two nucleoside analoguesAndrea Antinori, Amanda Clarke, Veronika Svedhem-Johansson, et al.
The Journal of Antimicrobial Chemotherapy|October 31, 2018
Effect of valaciclovir on CD4 count decline in untreated HIV: an international randomized controlled trialDarrell H S Tan, Janet M Raboud, Leah Szadkowski, et al.
Antiviral Therapy|March 24, 2020
Genital secretion HIV RNA shedding in HIV-positive patients on ritonavir-boosted protease inhibitor monotherapy or standard combination ART: a cross-sectional sub-study from the PIVOT TrialAlejandro Arenas-Pinto, Wolfgang Stöhr, Saye Khoo, et al.
Eclinicalmedicine|February 16, 2024
Long-term efficacy and safety of a treatment strategy for HIV infection using protease inhibitor monotherapy: 8-year routine clinical care follow-up from a randomised, controlled, open-label pragmatic trial (PIVOT)Nicholas I Paton, Wolfgang Stöhr, Alejandro Arenas-Pinto, et al.
Plos Medicine|June 18, 2021
Trends in HIV incidence between 2013-2019 and association of baseline factors with subsequent incident HIV among gay, bisexual, and other men who have sex with men attending sexual health clinics in England: A prospective cohort studyNadia Hanum, Valentina Cambiano, Janey Sewell, et al.
The Lancet. HIV|May 10, 2019
Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trialDavid A Wohl, Yazdan Yazdanpanah, Axel Baumgarten, et al.
Pageof 13